Protocol
11-013
Full Title
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma(AMC #075)
Purpose
The purpose of this study is to find the highest dose of the drug vorinostat that can be given safely with standard chemotherapy in patients with HIV-related diffuse large B-cell lymphoma (DLBCL). Vorinostat is approved for the treatment of another type of lymphoma called cutaneous T-cell lymphoma, but its use for DLBCL is considered investigational.
Patients will receive vorinostat with either rituximab and CHOP therapy (for those with low-risk DLBCL) or vorinostat with rituximab and EPOCH therapy (for patients with high-risk disease). Adding vorinostat to standard therapy may improve the treatment for this type of lymphoma.
Vorinostat may also have a positive effect against HIV and other viruses which can cause lymphoma. Doctors will be monitoring the effect of this treatment on HIV and other viruses in the blood.
Investigator
Co-Investigators
Eligibility
This study is for patients who:
- Have previously untreated DLBCL that is positive for the CD20+ protein (the target of rituximab).
- Have HIV infection.
- Are able to be ambulatory for more than half of their normal waking hours.
- Are age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.
Disease(s)
AIDS-Associated Cancers
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
Related Diseases
